Benefits from restructuring savings remain unchanged, and this yields an adjusted earnings per share range of $2.50 to $2.70, an increase of 21% to 31% over last year.
Earnings per share in the quarter was $0.56, which is up 143%.
For Xylem overall, we now see full-year 2021 organic revenue growth in the range of 5% to 7%, up from our previous guidance of 3% to 5%.
